LDL cholesterol-lowering treatment reduce risk of major vascular events

Objectives:
The benefits of LDL cholesterol-lowering treatment for the prevention of atherosclerotic cardiovascular disease are well established. However, the extent to which these effects differ by baseline LDL cholesterol, atherosclerotic cardiovascular disease risk and the presence of comorbidities remains uncertain. Therefore, this review article has been conducted.

Does LDL cholesterol-lowering treatment reduce risk of major vascular events (a composite of cardiovascular mortality, non-fatal myocardial infarction, non-fatal ischaemic stroke or coronary revascularisation)?

Study design:
This review article included 52 RCTs with a total of 327,037 patients.

Results and conclusions:
The investigators found each 1 mmol/L reduction in LDL cholesterol (bad cholesterol) was associated with a 19% relative risk (RR) reduction for major vascular events [RR = 0.81, 95% CI = 0.78 to 0.84,  p 0.0001].

The investigators found similar reductions (per 1 mmol/L reduction in LDL cholesterol) in trials with participants with LDL cholesterol level of 2.60 mmol/L or lower, 2.61-3.40 mmol/L, 3.41-4.10 mmol/L and more than 4.1 mmol/L [p = 0.232 for interaction] and in a subgroup of patients who all had a baseline LDL cholesterol level less than 2.07 mmol/L [80 mg/dL: RR = 0.83, 95% CI = 0.75-0.92, p = 0.001].

The investigators found greater RR reductions in patients at lower 10-year atherosclerotic cardiovascular disease risk [change in RR per 10% lower 10-year atherosclerotic cardiovascular disease = 0.97, 95% CI = 0.95 to 0.98, p 0.0001] and in patients at younger age across a mean age of 50-75 years [change in RR per 10 years younger age = 0.92, 95% CI = 0.83 to 0.97, p = 0.015].

The investigators found no difference in RR reduction for participants with or without diabetes [p = 0.878 for interaction] and chronic kidney disease [p = 0.934 for interaction].

The investigators concluded for each 1 mmol/L LDL cholesterol lowering, the risk reduction of major vascular events is independent of the starting LDL cholesterol or the presence of diabetes or chronic kidney disease. Patients at lower cardiovascular risk and younger age might have a similar relative reduction in risk with LDL-cholesterol lowering therapies and future studies should investigate the potential benefits of earlier intervention.

Original title:
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants by Wang N, Fulcher J, […], Lal S.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/31862150

Additional information of El Mondo:
Find more information/studies on lowering of cholesterol level and cardiovascular disease right here.